CTOs on the Move

Cortexyme

www.cortexyme.com

 
Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer`s and other neurodegenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cortexyme.com
  • 269 East Grand Avenue
    South San Francisco, CA USA 94080
  • Phone: 415.910.5717

Executives

Name Title Contact Details

Funding

Cortexyme raised $15M on 01/06/2016
Cortexyme raised $76M on 05/31/2018
Cortexyme raised $125M on 02/05/2020

Similar Companies

Jubilant Clinsys

Clinsys practices this philosophy with its clients. We focus on building long-term relationships and successful partnerships with our pharmaceutical and biotech partners through a total dedication to delivering on commitments, understanding client needs

Novascreen Biosciences Corporation

Novascreen Biosciences Corporation is a Hanover, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kinnos

Our patented and award-winning Highlight® technology makes it easy to use disinfectants correctly.

Omnicia

Omnicia is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cajal Neuroscience

Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.